President Donald Trump said makers of generic medicines will have to move production to the United States or face a 100% import duty starting in August 2028. The proposal targets imported low-cost drugs and could reshape how many widely used medicines reach the US market.
Generic drugs are a major source of affordable treatment for millions of Americans, so the plan is raising concerns about price pressure and supply stability. If manufacturers cannot relocate production fast enough, the added duty could make imported products far more expensive and disrupt access to lower-cost prescriptions.
The announcement also puts new focus on the global supply chain behind generic medicines. Many of these drugs are produced outside the US, and a sudden shift in manufacturing requirements could be difficult for companies that depend on existing overseas facilities.
While the policy is framed around bringing drug production back to the US, it also creates uncertainty for patients, manufacturers and health providers that rely on a steady flow of affordable generics. The biggest concern is whether the move would strengthen domestic production without limiting access to essential low-cost medicines.
